Molnupiravir - Revision history

Prab: CSV import

2025-03-23T18:58:55Z

CSV import

← Older revision		Revision as of 18:58, 23 March 2025
Line 1:		Line 1:
	'''Molnupiravir''' is an [[antiviral ~~drug]]~~ that is ~~currently under investigation for its potential use in the treatment of [[~~COVID-19]]. It was developed by the pharmaceutical companies [[Merck & Co.~~\|Merck]]~~ and [[~~Ridgeback Biotherapeutics~~]].		==Molnupiravir==

			[[File:MK-4482.svg\|Molnupiravir chemical structure\|thumb\|right]]

			'''Molnupiravir''' is an antiviral medication that is used to treat COVID-19. It was developed by the pharmaceutical companies Merck & Co. and Ridgeback Biotherapeutics. Molnupiravir is a prodrug of the synthetic nucleoside derivative N4-hydroxycytidine and exerts its antiviral action by introducing errors into the viral RNA during replication.

			==Mechanism of Action==

			Molnupiravir works by incorporating itself into the viral RNA. Once inside the viral RNA, it causes mutations during the replication process. These mutations accumulate and lead to "error catastrophe," which reduces the ability of the virus to replicate and spread.

			[[File:Molnupiravir_metabolism.svg\|Molnupiravir metabolism\|thumb\|left]]

			The drug is metabolized into its active form, N4-hydroxycytidine, which is then phosphorylated to the active triphosphate form. This active form is incorporated into the viral RNA by the viral RNA-dependent RNA polymerase.

			==Chemical Properties==

			Molnupiravir is a prodrug, meaning it is metabolized in the body to become an active pharmacological agent. Its chemical structure allows it to mimic the natural nucleosides used by the virus to replicate its RNA.

			==Synthesis==

	~~== History ==~~		[[File:Molnupiravir_synthesis.svg\|Molnupiravir synthesis\|thumb\|right]]

	~~Molnupiravir was initially developed for the treatment~~ of ~~[[influenza]]~~. ~~It was discovered by scientists at [[Emory University]] and is based on~~ the ~~compound [[~~N4-hydroxycytidine~~]]. The drug works by introducing errors into the [[RNA]] of the virus~~, which ~~prevents the virus from replicating~~.		The synthesis of molnupiravir involves several chemical reactions starting from uridine, a naturally occurring nucleoside. The process includes the introduction of a hydroxylamine group to form N4-hydroxycytidine, which is then converted into molnupiravir.

	== ~~Clinical Trials~~ ==		==Bonding and Interaction with Viral RNA==

	~~In 2020, Molnupiravir entered~~ [[~~Phase II clinical trials~~]] ~~for the treatment of COVID-19. Preliminary results from these trials have shown that the drug may reduce the duration of infectiousness for individuals with COVID-19.~~		[[File:Molnupiravir_GC_bonding.svg\|Molnupiravir GC bonding\|thumb\|left]]

	~~== Mechanism~~ of ~~Action ==~~		Molnupiravir can pair with both guanine and adenine, leading to G-to-A and C-to-U transitions in the viral genome. This dual pairing ability is crucial for its mechanism of inducing lethal mutagenesis in the virus.

	~~Molnupiravir works by introducing errors into the RNA of the virus, which prevents the virus from replicating. This is achieved through the drug's active metabolite,~~ [[~~EIDD-2801~~]]~~, which is incorporated into the virus's RNA.~~		[[File:Molnupiravir_AU_bonding.svg\|Molnupiravir AU bonding\|thumb\|right]]

	== ~~Potential Side Effects~~ ==		==Clinical Use==

	~~As with any drug,~~ Molnupiravir ~~may have potential side effects. These can include [[nausea]], [[diarrhea]],~~ and ~~[[headache]]~~. ~~However, these side effects~~ are ~~generally mild and temporary~~.		Molnupiravir is administered orally and is used in the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. It is typically prescribed for patients who cannot receive other treatments or for whom other treatments are not appropriate.

	== ~~See Also~~ ==		==Safety and Efficacy==

			Clinical trials have shown that molnupiravir can reduce the risk of hospitalization and death in patients with COVID-19. However, its use is subject to ongoing evaluation, and it is important to consider potential side effects and contraindications.

			==Related Pages==

	* [[COVID-19 pandemic]]		* [[COVID-19 pandemic]]
	* [[Antiviral drug]]		* [[Antiviral drug]]
	* [[~~Clinical trial~~]]		* [[RNA virus]]
	* [[~~RNA~~]]		* [[Merck & Co.]]

	{{~~stub~~}}		{{COVID-19 pandemic}}
			{{Antiviral drugs}}

	~~[[Category:Medicine]]~~
	~~[[Category:Pharmacology]]~~
	~~[[Category:COVID-19]]~~
	[[Category:Antiviral drugs]]		[[Category:Antiviral drugs]]
	~~==Molnupiravir==~~		[[Category:COVID-19 pandemic]]
	~~<gallery>~~		[[Category:Experimental drugs]]
	~~File~~:MK-~~4482.svg\|Molnupiravir chemical structure~~
	~~File:Molnupiravir metabolism.svg\|Molnupiravir metabolism~~
	~~File:Molnupiravir GC bonding.svg\|Molnupiravir GC bonding~~
	~~File:Molnupiravir AU bonding.svg\|Molnupiravir AU bonding~~
	~~File~~:~~Molnupiravir synthesis.svg\|Molnupiravir synthesis~~
	~~</gallery>~~
	~~==Molnupiravir==~~
	~~<gallery>~~
	~~File:MK-4482.svg\|Molnupiravir chemical structure~~
	~~File:Molnupiravir metabolism.svg\|Molnupiravir metabolism~~
	~~File:Molnupiravir GC bonding.svg\|Molnupiravir GC bonding~~
	~~File:Molnupiravir AU bonding.svg\|Molnupiravir AU bonding~~
	~~File:Molnupiravir synthesis.svg\|Molnupiravir synthesis~~
	~~</gallery>~~

Prab: CSV import

2025-02-20T01:32:22Z

CSV import

← Older revision		Revision as of 01:32, 20 February 2025
Line 30:		Line 30:
	[[Category:COVID-19]]		[[Category:COVID-19]]
	[[Category:Antiviral drugs]]		[[Category:Antiviral drugs]]
			==Molnupiravir==
			<gallery>
			File:MK-4482.svg\|Molnupiravir chemical structure
			File:Molnupiravir metabolism.svg\|Molnupiravir metabolism
			File:Molnupiravir GC bonding.svg\|Molnupiravir GC bonding
			File:Molnupiravir AU bonding.svg\|Molnupiravir AU bonding
			File:Molnupiravir synthesis.svg\|Molnupiravir synthesis
			</gallery>
	==Molnupiravir==		==Molnupiravir==
	<gallery>		<gallery>

Prab: CSV import

2025-02-20T01:13:16Z

CSV import

← Older revision		Revision as of 01:13, 20 February 2025
Line 30:		Line 30:
	[[Category:COVID-19]]		[[Category:COVID-19]]
	[[Category:Antiviral drugs]]		[[Category:Antiviral drugs]]
			==Molnupiravir==
			<gallery>
			File:MK-4482.svg\|Molnupiravir chemical structure
			File:Molnupiravir metabolism.svg\|Molnupiravir metabolism
			File:Molnupiravir GC bonding.svg\|Molnupiravir GC bonding
			File:Molnupiravir AU bonding.svg\|Molnupiravir AU bonding
			File:Molnupiravir synthesis.svg\|Molnupiravir synthesis
			</gallery>

Prab: CSV import

2024-02-21T05:53:16Z

CSV import

New page

'''Molnupiravir''' is an [[antiviral drug]] that is currently under investigation for its potential use in the treatment of [[COVID-19]]. It was developed by the pharmaceutical companies [[Merck & Co.|Merck]] and [[Ridgeback Biotherapeutics]].

== History ==

Molnupiravir was initially developed for the treatment of [[influenza]]. It was discovered by scientists at [[Emory University]] and is based on the compound [[N4-hydroxycytidine]]. The drug works by introducing errors into the [[RNA]] of the virus, which prevents the virus from replicating.

== Clinical Trials ==

In 2020, Molnupiravir entered [[Phase II clinical trials]] for the treatment of COVID-19. Preliminary results from these trials have shown that the drug may reduce the duration of infectiousness for individuals with COVID-19.

== Mechanism of Action ==

Molnupiravir works by introducing errors into the RNA of the virus, which prevents the virus from replicating. This is achieved through the drug's active metabolite, [[EIDD-2801]], which is incorporated into the virus's RNA.

== Potential Side Effects ==

As with any drug, Molnupiravir may have potential side effects. These can include [[nausea]], [[diarrhea]], and [[headache]]. However, these side effects are generally mild and temporary.

== See Also ==

* [[COVID-19 pandemic]]
* [[Antiviral drug]]
* [[Clinical trial]]
* [[RNA]]

{{stub}}

[[Category:Medicine]]
[[Category:Pharmacology]]
[[Category:COVID-19]]
[[Category:Antiviral drugs]]